Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12658772,Cmax,"The main parameters of irbesartan capsules were: Cmax: 1.502 +/- 0.295 micrograms/ml, tmax: 1.44 +/- 0.34 h, t 1/2: 20.21 +/- 14.71 h, AUC0-t: 11.087 +/- 3.443 micrograms/ml-1.h.",Study on the pharmacokinetics and relative bioavailability of irbesartan capsules in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658772/),[μg] / [ml],1.502,13150,DB01029,Irbesartan
,12658772,tmax,"The main parameters of irbesartan capsules were: Cmax: 1.502 +/- 0.295 micrograms/ml, tmax: 1.44 +/- 0.34 h, t 1/2: 20.21 +/- 14.71 h, AUC0-t: 11.087 +/- 3.443 micrograms/ml-1.h.",Study on the pharmacokinetics and relative bioavailability of irbesartan capsules in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658772/),h,1.44,13151,DB01029,Irbesartan
,12658772,t 1/2,"The main parameters of irbesartan capsules were: Cmax: 1.502 +/- 0.295 micrograms/ml, tmax: 1.44 +/- 0.34 h, t 1/2: 20.21 +/- 14.71 h, AUC0-t: 11.087 +/- 3.443 micrograms/ml-1.h.",Study on the pharmacokinetics and relative bioavailability of irbesartan capsules in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658772/),h,20.21,13152,DB01029,Irbesartan
,12658772,AUC0-t,"The main parameters of irbesartan capsules were: Cmax: 1.502 +/- 0.295 micrograms/ml, tmax: 1.44 +/- 0.34 h, t 1/2: 20.21 +/- 14.71 h, AUC0-t: 11.087 +/- 3.443 micrograms/ml-1.h.",Study on the pharmacokinetics and relative bioavailability of irbesartan capsules in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658772/),[μg] / [ml],11.087,13153,DB01029,Irbesartan
,12658772,relative bioavailability,The relative bioavailability of capsule to tablet was (101.4 +/- 28.9)%.,Study on the pharmacokinetics and relative bioavailability of irbesartan capsules in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12658772/),%,101.4,13154,DB01029,Irbesartan
,32152915,flow rates,"This model exhibited sustained intestinal supersaturation (2-4-fold) even upon varying flow rates (4 mL/min, 7 mL/min, and mono-exponential transfer) from gastric to intestinal compartment.",Understanding the Oral Absorption of Irbesartan Using Biorelevant Dissolution Testing and PBPK Modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152915/),[ml] / [min],4,26372,DB01029,Irbesartan
,32152915,flow rates,"This model exhibited sustained intestinal supersaturation (2-4-fold) even upon varying flow rates (4 mL/min, 7 mL/min, and mono-exponential transfer) from gastric to intestinal compartment.",Understanding the Oral Absorption of Irbesartan Using Biorelevant Dissolution Testing and PBPK Modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32152915/),[ml] / [min],7,26373,DB01029,Irbesartan
,20872901,limit of detection,The limit of detection is 0.01 ng/ml and the lower limit of quantitation (LLOQ) is 0.20 ng/ml.,Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20872901/),[ng] / [ml],0.01,27310,DB01029,Irbesartan
,25947361,total run time,"After solid-phase extraction, the analytes and internal standard (irbesartan) were extracted from 100 µL plasma sample on an Agilent Poroshell 120, EC-C18 (50 × 4.6 mm, i.d., 2.7 µm) column using 5 µL injection volume with a total run time of 3 min.","Simultaneous Determination and Pharmacokinetics of Metolazone, Losartan and Losartan Carboxylic Acid in Rat Plasma by HPLC-ESI-MS-MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25947361/),min,3,29789,DB01029,Irbesartan
,17655373,Renal clearance,"Renal clearance of aliskiren averaged 1280 +/- 500 mL/hour (mean +/- SD) in healthy subjects and 559 +/- 220, 312 +/- 75 and 243 +/- 186 mL/hour in patients with mild, moderate and severe renal impairment, respectively.",Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655373/),[ml] / [h],1280,53870,DB01029,Irbesartan
,17655373,Renal clearance,"Renal clearance of aliskiren averaged 1280 +/- 500 mL/hour (mean +/- SD) in healthy subjects and 559 +/- 220, 312 +/- 75 and 243 +/- 186 mL/hour in patients with mild, moderate and severe renal impairment, respectively.",Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655373/),[ml] / [h],559,53871,DB01029,Irbesartan
,17655373,Renal clearance,"Renal clearance of aliskiren averaged 1280 +/- 500 mL/hour (mean +/- SD) in healthy subjects and 559 +/- 220, 312 +/- 75 and 243 +/- 186 mL/hour in patients with mild, moderate and severe renal impairment, respectively.",Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655373/),[ml] / [h],312,53872,DB01029,Irbesartan
,17655373,Renal clearance,"Renal clearance of aliskiren averaged 1280 +/- 500 mL/hour (mean +/- SD) in healthy subjects and 559 +/- 220, 312 +/- 75 and 243 +/- 186 mL/hour in patients with mild, moderate and severe renal impairment, respectively.",Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655373/),[ml] / [h],243,53873,DB01029,Irbesartan
,9449566,flow-rate,"The mobile phase consisted of 50% acetonitrile and a 50% weak phosphate-triethylamine solution, pH 3.5, at a flow-rate of 0.8 ml/min.",High-performance liquid chromatographic assay for the quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449566/),[ml] / [min],0.8,79737,DB01029,Irbesartan
,10684525,area under the curve,Irbesartan-treated patients had significantly greater 24-hour area under the curve values for mean change from baseline in AII and PRA versus placebo-treated patients on day B15 (AII [pg |mZ h/mL]: 261 +/- 515 vs 12 +/- 51; PRA [(ng/mL/h); h]:74 +/-162 vs -2 +/-14; P values >.05).,Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate Hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684525/),[h·pg·|mz] / [ml],261,81641,DB01029,Irbesartan
,10684525,area under the curve,Irbesartan-treated patients had significantly greater 24-hour area under the curve values for mean change from baseline in AII and PRA versus placebo-treated patients on day B15 (AII [pg |mZ h/mL]: 261 +/- 515 vs 12 +/- 51; PRA [(ng/mL/h); h]:74 +/-162 vs -2 +/-14; P values >.05).,Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate Hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684525/),[h·pg·|mz] / [ml],12,81642,DB01029,Irbesartan
,10684525,area under the curve,Irbesartan-treated patients had significantly greater 24-hour area under the curve values for mean change from baseline in AII and PRA versus placebo-treated patients on day B15 (AII [pg |mZ h/mL]: 261 +/- 515 vs 12 +/- 51; PRA [(ng/mL/h); h]:74 +/-162 vs -2 +/-14; P values >.05).,Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate Hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684525/),[ng] / [h·h);·ml],74,81643,DB01029,Irbesartan
,10684525,area under the curve,Irbesartan-treated patients had significantly greater 24-hour area under the curve values for mean change from baseline in AII and PRA versus placebo-treated patients on day B15 (AII [pg |mZ h/mL]: 261 +/- 515 vs 12 +/- 51; PRA [(ng/mL/h); h]:74 +/-162 vs -2 +/-14; P values >.05).,Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate Hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684525/),[ng] / [h·h);·ml],2,81644,DB01029,Irbesartan
,33880775,flow rate,"After extraction, the prepared samples were run on an Agilent Welchrom C18 column with the mobile phase consisting of methanol-acetonitrile-water solution with 0.5% formic acid (45:50:5, v/v/v) at a flow rate of 0.8 mL·min-1 .",A rapid LC-MS/MS method for simultaneous determination of berberine and irbesartan in rat plasma: Application to the drug-drug pharmacokinetic interaction study after oral administration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33880775/),[ml] / [min],0.8,83292,DB01029,Irbesartan
,33880775,m/,"The analytes BBR, irbesartan, and diphenhydramine (IS) were detected using multiple reactions monitoring mode, with the ion transitions being m/z 336.1 → m/z 320.0, m/z 429.1 → m/z 206.9, and m/z 256.2 → m/z 167.0, respectively.",A rapid LC-MS/MS method for simultaneous determination of berberine and irbesartan in rat plasma: Application to the drug-drug pharmacokinetic interaction study after oral administration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33880775/),,429.1,83293,DB01029,Irbesartan
,33880775,m/z,"The analytes BBR, irbesartan, and diphenhydramine (IS) were detected using multiple reactions monitoring mode, with the ion transitions being m/z 336.1 → m/z 320.0, m/z 429.1 → m/z 206.9, and m/z 256.2 → m/z 167.0, respectively.",A rapid LC-MS/MS method for simultaneous determination of berberine and irbesartan in rat plasma: Application to the drug-drug pharmacokinetic interaction study after oral administration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33880775/),,256.2,83294,DB01029,Irbesartan
,17315536,Emax,"The Emax values for the inhibitory effects on SBP and DBP of irbesartan were 14.8 +/- 1.5 and 9.8 +/- 2.1 mmHg respectively, the EC50 values were 0.29 +/- 0.11 and 0.18 +/- 0.07 microg x ml(-1), while the K(eo) values were 0.62 +/- 0.09 and 0.68 +/- 0.07 h(-1), respectively.",PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315536/),mmhg,14.8,90362,DB01029,Irbesartan
,17315536,Emax,"The Emax values for the inhibitory effects on SBP and DBP of irbesartan were 14.8 +/- 1.5 and 9.8 +/- 2.1 mmHg respectively, the EC50 values were 0.29 +/- 0.11 and 0.18 +/- 0.07 microg x ml(-1), while the K(eo) values were 0.62 +/- 0.09 and 0.68 +/- 0.07 h(-1), respectively.",PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315536/),mmhg,9.8,90363,DB01029,Irbesartan
,17315536,EC50,"The Emax values for the inhibitory effects on SBP and DBP of irbesartan were 14.8 +/- 1.5 and 9.8 +/- 2.1 mmHg respectively, the EC50 values were 0.29 +/- 0.11 and 0.18 +/- 0.07 microg x ml(-1), while the K(eo) values were 0.62 +/- 0.09 and 0.68 +/- 0.07 h(-1), respectively.",PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315536/),[μg] / [ml],0.29,90364,DB01029,Irbesartan
,17315536,EC50,"The Emax values for the inhibitory effects on SBP and DBP of irbesartan were 14.8 +/- 1.5 and 9.8 +/- 2.1 mmHg respectively, the EC50 values were 0.29 +/- 0.11 and 0.18 +/- 0.07 microg x ml(-1), while the K(eo) values were 0.62 +/- 0.09 and 0.68 +/- 0.07 h(-1), respectively.",PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315536/),[μg] / [ml],0.18,90365,DB01029,Irbesartan
,17315536,K(eo),"The Emax values for the inhibitory effects on SBP and DBP of irbesartan were 14.8 +/- 1.5 and 9.8 +/- 2.1 mmHg respectively, the EC50 values were 0.29 +/- 0.11 and 0.18 +/- 0.07 microg x ml(-1), while the K(eo) values were 0.62 +/- 0.09 and 0.68 +/- 0.07 h(-1), respectively.",PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315536/),1/[h],0.62,90366,DB01029,Irbesartan
,17315536,K(eo),"The Emax values for the inhibitory effects on SBP and DBP of irbesartan were 14.8 +/- 1.5 and 9.8 +/- 2.1 mmHg respectively, the EC50 values were 0.29 +/- 0.11 and 0.18 +/- 0.07 microg x ml(-1), while the K(eo) values were 0.62 +/- 0.09 and 0.68 +/- 0.07 h(-1), respectively.",PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17315536/),1/[h],0.68,90367,DB01029,Irbesartan
,12667927,Ke,"The estimated Ke from MD and BS were similar (MD: 1.8+/-0.3 h(-1), n=5; BS: 1.7+/-0.2 h(-1), n=5).",Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667927/),1/[h],1.8,95315,DB01029,Irbesartan
,12667927,Ke,"The estimated Ke from MD and BS were similar (MD: 1.8+/-0.3 h(-1), n=5; BS: 1.7+/-0.2 h(-1), n=5).",Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667927/),1/[h],1.7,95316,DB01029,Irbesartan
,12667927,volume of distribution (Vd),"After protein binding correction for the MD, the estimated values of volume of distribution (Vd) (MD: 1.2+/-0.4 l, n=5; BS: 1.1+/-0.4 l, n=5), clearance (Cl) (MD: 32.3+/-7.3 ml min(-1), n=5; BS: 30.7+/-8.2 ml min(-1), n=5) and AUC (MD: 7.7+/-3.2 microg x ml(-1) h, n=5; BS: 8.8+/-3.4 microg x ml(-1) h, n=5) were similar between MD and BS.",Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667927/),l,1.2,95317,DB01029,Irbesartan
,12667927,volume of distribution (Vd),"After protein binding correction for the MD, the estimated values of volume of distribution (Vd) (MD: 1.2+/-0.4 l, n=5; BS: 1.1+/-0.4 l, n=5), clearance (Cl) (MD: 32.3+/-7.3 ml min(-1), n=5; BS: 30.7+/-8.2 ml min(-1), n=5) and AUC (MD: 7.7+/-3.2 microg x ml(-1) h, n=5; BS: 8.8+/-3.4 microg x ml(-1) h, n=5) were similar between MD and BS.",Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667927/),l,1.1,95318,DB01029,Irbesartan
,12667927,clearance (Cl),"After protein binding correction for the MD, the estimated values of volume of distribution (Vd) (MD: 1.2+/-0.4 l, n=5; BS: 1.1+/-0.4 l, n=5), clearance (Cl) (MD: 32.3+/-7.3 ml min(-1), n=5; BS: 30.7+/-8.2 ml min(-1), n=5) and AUC (MD: 7.7+/-3.2 microg x ml(-1) h, n=5; BS: 8.8+/-3.4 microg x ml(-1) h, n=5) were similar between MD and BS.",Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667927/),[ml] / [min],32.3,95319,DB01029,Irbesartan
,12667927,clearance (Cl),"After protein binding correction for the MD, the estimated values of volume of distribution (Vd) (MD: 1.2+/-0.4 l, n=5; BS: 1.1+/-0.4 l, n=5), clearance (Cl) (MD: 32.3+/-7.3 ml min(-1), n=5; BS: 30.7+/-8.2 ml min(-1), n=5) and AUC (MD: 7.7+/-3.2 microg x ml(-1) h, n=5; BS: 8.8+/-3.4 microg x ml(-1) h, n=5) were similar between MD and BS.",Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667927/),[ml] / [min],30.7,95320,DB01029,Irbesartan
,12667927,AUC,"After protein binding correction for the MD, the estimated values of volume of distribution (Vd) (MD: 1.2+/-0.4 l, n=5; BS: 1.1+/-0.4 l, n=5), clearance (Cl) (MD: 32.3+/-7.3 ml min(-1), n=5; BS: 30.7+/-8.2 ml min(-1), n=5) and AUC (MD: 7.7+/-3.2 microg x ml(-1) h, n=5; BS: 8.8+/-3.4 microg x ml(-1) h, n=5) were similar between MD and BS.",Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667927/),[h·μg] / [ml],7.7,95321,DB01029,Irbesartan
,12667927,AUC,"After protein binding correction for the MD, the estimated values of volume of distribution (Vd) (MD: 1.2+/-0.4 l, n=5; BS: 1.1+/-0.4 l, n=5), clearance (Cl) (MD: 32.3+/-7.3 ml min(-1), n=5; BS: 30.7+/-8.2 ml min(-1), n=5) and AUC (MD: 7.7+/-3.2 microg x ml(-1) h, n=5; BS: 8.8+/-3.4 microg x ml(-1) h, n=5) were similar between MD and BS.",Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12667927/),[h·μg] / [ml],8.8,95322,DB01029,Irbesartan
,24725445,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) of 3,617.19 and 3,295.77 ng/mL for test and reference, respectively, were achieved.",Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725445/),[ng] / [ml],"3,617.19",108177,DB01029,Irbesartan
,24725445,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax) of 3,617.19 and 3,295.77 ng/mL for test and reference, respectively, were achieved.",Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725445/),[ng] / [ml],"3,295.77",108178,DB01029,Irbesartan
,24725445,Areas under the plasma concentration-time curve,"Areas under the plasma concentration-time curve; AUC0-t and AUC0-∞ were 15,304.65 and 15,638.90 ng×h/mL for test and 15,389.21 and 15,730.34 ng×h/mL for reference.",Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725445/),[h·ng] / [ml],"15,304.65",108179,DB01029,Irbesartan
,24725445,Areas under the plasma concentration-time curve,"Areas under the plasma concentration-time curve; AUC0-t and AUC0-∞ were 15,304.65 and 15,638.90 ng×h/mL for test and 15,389.21 and 15,730.34 ng×h/mL for reference.",Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725445/),[h·ng] / [ml],"15,389.21",108180,DB01029,Irbesartan
,24725445,AUC0-t,"Areas under the plasma concentration-time curve; AUC0-t and AUC0-∞ were 15,304.65 and 15,638.90 ng×h/mL for test and 15,389.21 and 15,730.34 ng×h/mL for reference.",Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725445/),[h·ng] / [ml],"15,638.90",108181,DB01029,Irbesartan
,24725445,AUC0-t,"Areas under the plasma concentration-time curve; AUC0-t and AUC0-∞ were 15,304.65 and 15,638.90 ng×h/mL for test and 15,389.21 and 15,730.34 ng×h/mL for reference.",Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725445/),[h·ng] / [ml],"15,389.21",108182,DB01029,Irbesartan
,24725445,AUC0-∞,"Areas under the plasma concentration-time curve; AUC0-t and AUC0-∞ were 15,304.65 and 15,638.90 ng×h/mL for test and 15,389.21 and 15,730.34 ng×h/mL for reference.",Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725445/),[h·ng] / [ml],"15,730.34",108183,DB01029,Irbesartan
,24725445,tmax,"The median tmax was 1.50 hours and 1.25 hours for test and reference, respectively.",Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725445/),h,1.50,108184,DB01029,Irbesartan
,24725445,tmax,"The median tmax was 1.50 hours and 1.25 hours for test and reference, respectively.",Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725445/),h,1.25,108185,DB01029,Irbesartan
,24725445,Plasma elimination half-lives (t1/2),"Plasma elimination half-lives (t1/2) were 7.35 hours and 8.09 hours for test and reference, respectively.",Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725445/),h,7.35,108186,DB01029,Irbesartan
,24725445,Plasma elimination half-lives (t1/2),"Plasma elimination half-lives (t1/2) were 7.35 hours and 8.09 hours for test and reference, respectively.",Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24725445/),h,8.09,108187,DB01029,Irbesartan
,9725545,absolute oral bioavailability,"Irbesartan was rapidly and almost completely absorbed after oral administration, and exhibited a mean absolute oral bioavailability of 60% to 80%.","Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725545/),%,60,112357,DB01029,Irbesartan
,9725545,absolute oral bioavailability,"Irbesartan was rapidly and almost completely absorbed after oral administration, and exhibited a mean absolute oral bioavailability of 60% to 80%.","Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725545/),%,80,112358,DB01029,Irbesartan
,9725545,total body clearance,"Mean total body clearance was approximately 157 mL/min, and renal clearance was 3.0 mL/min.","Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725545/),[ml] / [min],157,112359,DB01029,Irbesartan
,9725545,renal clearance,"Mean total body clearance was approximately 157 mL/min, and renal clearance was 3.0 mL/min.","Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725545/),[ml] / [min],3.0,112360,DB01029,Irbesartan
,9725545,Volume of distribution at steady state,"Volume of distribution at steady state was 53 L to 93 L, and terminal elimination half-life was approximately 13 to 16 hours.","Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725545/),l,53,112361,DB01029,Irbesartan
,9725545,Volume of distribution at steady state,"Volume of distribution at steady state was 53 L to 93 L, and terminal elimination half-life was approximately 13 to 16 hours.","Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725545/),l,93,112362,DB01029,Irbesartan
,9725545,terminal elimination half-life,"Volume of distribution at steady state was 53 L to 93 L, and terminal elimination half-life was approximately 13 to 16 hours.","Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725545/),h,13 to 16,112363,DB01029,Irbesartan
,9725545,Hepatic extraction ratio,Hepatic extraction ratio was low (0.2).,"Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725545/),,0.2,112364,DB01029,Irbesartan
,34070168,Cmax,"Within 0.5 h after single administration, the Cmax of irbesartan and candesartan in retinal tissue was 251 ± 142 ng/g and 63 ± 39 ng/g, respectively.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],251,121977,DB01029,Irbesartan
,34070168,Cmax,"Within 0.5 h after single administration, the Cmax of irbesartan and candesartan in retinal tissue was 251 ± 142 ng/g and 63 ± 39 ng/g, respectively.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],63,121978,DB01029,Irbesartan
,34070168,Cmax,"In the vitreous humor, a Cmax of 14 ± 16 ng/g for irbesartan was reached 0.5 h after instillation while Cmax was below 2 ng/g for candesartan.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],14,121979,DB01029,Irbesartan
below,34070168,Cmax,"In the vitreous humor, a Cmax of 14 ± 16 ng/g for irbesartan was reached 0.5 h after instillation while Cmax was below 2 ng/g for candesartan.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],2,121980,DB01029,Irbesartan
,34070168,Cmean,"For multiple dosing, the observed Cmean in retinal tissue was 338 ± 124 ng/g for irbesartan and 36 ± 10 ng/g for candesartan, whereas mean vitreous humor concentrations were 13 ± 5 ng/g and <2 ng/g, respectively.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],338,121981,DB01029,Irbesartan
,34070168,Cmean,"For multiple dosing, the observed Cmean in retinal tissue was 338 ± 124 ng/g for irbesartan and 36 ± 10 ng/g for candesartan, whereas mean vitreous humor concentrations were 13 ± 5 ng/g and <2 ng/g, respectively.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],36,121982,DB01029,Irbesartan
,34070168,concentrations,"For multiple dosing, the observed Cmean in retinal tissue was 338 ± 124 ng/g for irbesartan and 36 ± 10 ng/g for candesartan, whereas mean vitreous humor concentrations were 13 ± 5 ng/g and <2 ng/g, respectively.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],13,121983,DB01029,Irbesartan
<,34070168,concentrations,"For multiple dosing, the observed Cmean in retinal tissue was 338 ± 124 ng/g for irbesartan and 36 ± 10 ng/g for candesartan, whereas mean vitreous humor concentrations were 13 ± 5 ng/g and <2 ng/g, respectively.",Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [g],2,121984,DB01029,Irbesartan
,34070168,Cmax,The highest plasma concentrations of both irbesartan (Cmax 5.64 ± 4.08 ng/mL) and candesartan (Cmax 4.32 ± 1.04 ng/mL) were reached 0.5 h (Tmax) after single administration.,Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [ml],5.64,121985,DB01029,Irbesartan
,34070168,Cmax,The highest plasma concentrations of both irbesartan (Cmax 5.64 ± 4.08 ng/mL) and candesartan (Cmax 4.32 ± 1.04 ng/mL) were reached 0.5 h (Tmax) after single administration.,Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),[ng] / [ml],4.32,121986,DB01029,Irbesartan
,34070168,Tmax,The highest plasma concentrations of both irbesartan (Cmax 5.64 ± 4.08 ng/mL) and candesartan (Cmax 4.32 ± 1.04 ng/mL) were reached 0.5 h (Tmax) after single administration.,Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34070168/),h,0.5,121987,DB01029,Irbesartan
,28911717,flow rate,"After a simple protein precipitation using methanol and acetonitrile, IRB and internal standard (IS) telmisartan were separated on Acquity UPLC BEH C18 column (50 mm × 2.1 mm, i.d. 1.7 μm, Waters, Milford, MA, USA) using a mobile phase consisted of acetonitrile: methanol: 10 mM ammonium acetate (70: 15: 15 v/v/v) with a flow rate of 0.4 mL/min and detected MS/MS in negative ion mode.",New ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of irbesartan in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28911717/),[ml] / [min],0.4,126224,DB01029,Irbesartan
,28911717,m/z,The ion transitions recorded in multiple reaction monitoring mode were m/z 427.2→193.08 for IRB and m/z 513.2→469.3 for IS.,New ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of irbesartan in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28911717/),,427.2,126225,DB01029,Irbesartan
,28911717,m/z,The ion transitions recorded in multiple reaction monitoring mode were m/z 427.2→193.08 for IRB and m/z 513.2→469.3 for IS.,New ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of irbesartan in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28911717/),,513.2,126226,DB01029,Irbesartan
,24195292,minimum effective concentration,The minimum effective concentration was theorized to be within the range 550-800 ng/mL.,Pharmacokinetics and pharmacodynamics (PK/PD) of irbesartan in Beagle dogs after oral administration at two dose rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24195292/),[ng] / [ml],550-800,150314,DB01029,Irbesartan
,9438775,oral bioavailability,"Irbesartan has the highest oral bioavailability in its class (60% to 80%) and, unlike valsartan, its absorption is not affected by food.","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),%,60,165770,DB01029,Irbesartan
,9438775,oral bioavailability,"Irbesartan has the highest oral bioavailability in its class (60% to 80%) and, unlike valsartan, its absorption is not affected by food.","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),%,80,165771,DB01029,Irbesartan
,9438775,elimination half-life,"Irbesartan displays linear, dose related pharmacokinetics and, with the exception of tasosartan's active metabolite, has the longest elimination half-life of the AIIRA (11 to 15 h).","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),h,11 to 15,165772,DB01029,Irbesartan
,31181484,flow rate,"The two analytes were extracted from plasma sample using acetonitrile-induced protein precipitation then separated on an Agilent Eclipse Plus ODS (4.6 × 100 mm, 3.5 μm) column by gradient elution using 6 mM ammonium formate/0.1% formic acid and ACN at a flow rate 0.4 mL min-1.",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),[ml] / [min],0.4,167338,DB01029,Irbesartan
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,492.1,167339,DB01029,Irbesartan
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,206,167340,DB01029,Irbesartan
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,482.1,167341,DB01029,Irbesartan
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,258.1,167342,DB01029,Irbesartan
,31181484,m/,"Multiple reaction monitoring in positive ion mode was used for quantification of precursor to production at m/z 492.1 → 206.9 for IRB, 482.1 → 258.1 for ROS, and 409.2 → 238.2 for the internal standard, amlodipine (AML).",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),,409.2,167343,DB01029,Irbesartan
,31181484,detection limits (S/N of 3),"Linearity was obeyed in the range of 1-10000 ng mL-1 and 1-5000 ng mL-1 with detection limits (S/N of 3) of 0.05 and 0.07 ng mL-1 for IRB and ROS, respectively.",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),[ng] / [ml],0.05,167344,DB01029,Irbesartan
,31181484,detection limits (S/N of 3),"Linearity was obeyed in the range of 1-10000 ng mL-1 and 1-5000 ng mL-1 with detection limits (S/N of 3) of 0.05 and 0.07 ng mL-1 for IRB and ROS, respectively.",An LC-MS/MS spectrometry method for the simultaneous determination of Rosuvastatin and Irbesartan in rat plasma: Insight into pharmacokinetic and drug-drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31181484/),[ng] / [ml],0.07,167345,DB01029,Irbesartan
,32736091,ka,"Parameters estimated were: the absorption rate constant in the central compartment (ka = 0.304 h-1), the constant time delay between the administration and the absorption (T=1.68 h), the apparent volume of distribution of the central (V1/F = 13.8 L) and peripheral (V2/F = 85.8 L) compartment, the apparent clearance from the central compartment (CL/F = 13.5 L/h), and the inter-compartmental clearance (Q/F = 17.7 L/h).",Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32736091/),1/[h],0.304,171356,DB01029,Irbesartan
,32736091,apparent volume of distribution of the central (V1/F,"Parameters estimated were: the absorption rate constant in the central compartment (ka = 0.304 h-1), the constant time delay between the administration and the absorption (T=1.68 h), the apparent volume of distribution of the central (V1/F = 13.8 L) and peripheral (V2/F = 85.8 L) compartment, the apparent clearance from the central compartment (CL/F = 13.5 L/h), and the inter-compartmental clearance (Q/F = 17.7 L/h).",Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32736091/),l,13.8,171357,DB01029,Irbesartan
,32736091,V2/F,"Parameters estimated were: the absorption rate constant in the central compartment (ka = 0.304 h-1), the constant time delay between the administration and the absorption (T=1.68 h), the apparent volume of distribution of the central (V1/F = 13.8 L) and peripheral (V2/F = 85.8 L) compartment, the apparent clearance from the central compartment (CL/F = 13.5 L/h), and the inter-compartmental clearance (Q/F = 17.7 L/h).",Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32736091/),l,85.8,171358,DB01029,Irbesartan
,32736091,apparent clearance from the central compartment (CL/F,"Parameters estimated were: the absorption rate constant in the central compartment (ka = 0.304 h-1), the constant time delay between the administration and the absorption (T=1.68 h), the apparent volume of distribution of the central (V1/F = 13.8 L) and peripheral (V2/F = 85.8 L) compartment, the apparent clearance from the central compartment (CL/F = 13.5 L/h), and the inter-compartmental clearance (Q/F = 17.7 L/h).",Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32736091/),[l] / [h],13.5,171359,DB01029,Irbesartan
,32736091,Q/F,"Parameters estimated were: the absorption rate constant in the central compartment (ka = 0.304 h-1), the constant time delay between the administration and the absorption (T=1.68 h), the apparent volume of distribution of the central (V1/F = 13.8 L) and peripheral (V2/F = 85.8 L) compartment, the apparent clearance from the central compartment (CL/F = 13.5 L/h), and the inter-compartmental clearance (Q/F = 17.7 L/h).",Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32736091/),[l] / [h],17.7,171360,DB01029,Irbesartan
,12504198,flow-rate,Good chromatographic separation was achieved using a Supelcocil C(18) (5 micrometer 15 cmx4.6 mm) column and a mobile phase consisting of 10 mM potassium dihydrogen phosphate:methanol:acetonitrile (5:80:15 v/v/v) (pH:2.5) while at a flow-rate of 1.0 ml min(-1).,Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504198/),[ml] / [min],1.0,177100,DB01029,Irbesartan
,29403914,constant flow rate,"The chromatographic separation was achieved on Luna-HILIC (250 mm×4.6 mm, 5 μm) column with a mobile phase of 0.1% of formic acid in water:acetonitrile (5: 95, v/v), at a constant flow rate of 1.0 mL/min.",Direct injection HILIC-MS/MS analysis of darunavir in rat plasma applying supported liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403914/),[ml] / [min],1.0,178588,DB01029,Irbesartan
,19277953,flow-rate,"An isocratic mobile phase, acetonitrile:0.1% formic acid (37:63, v/v), was run at a flow-rate of 1.0 mL/min, and the column eluent was monitored using a fluorescence detector set at excitation and emission wavelengths of 250 and 370 nm, respectively.",HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277953/),[ml] / [min],1.0,180383,DB01029,Irbesartan
,19277953,retention times,"The retention times of irbesartan and losartan were 4.4 and 5.9 min, respectively.",HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277953/),min,4.4,180384,DB01029,Irbesartan
,19277953,retention times,"The retention times of irbesartan and losartan were 4.4 and 5.9 min, respectively.",HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277953/),min,5.9,180385,DB01029,Irbesartan
,19277953,relative recoveries,"The mean relative recoveries of irbesartan and losartan were 98.4 and 99.1%, respectively.",HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277953/),%,98.4,180386,DB01029,Irbesartan
,19277953,relative recoveries,"The mean relative recoveries of irbesartan and losartan were 98.4 and 99.1%, respectively.",HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277953/),%,99.1,180387,DB01029,Irbesartan
,10934672,AUC0-infinity,The mean AUC0-infinity of total simvastatin acid was 74.55 ng x h/mL when simvastatin was given alone and 67.55 ng x h/mL when simvastatin and irbesartan were given concomitantly.,Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934672/),[h·ng] / [ml],74.55,181395,DB01029,Irbesartan
,10934672,AUC0-infinity,The mean AUC0-infinity of total simvastatin acid was 74.55 ng x h/mL when simvastatin was given alone and 67.55 ng x h/mL when simvastatin and irbesartan were given concomitantly.,Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934672/),[h·ng] / [ml],67.55,181396,DB01029,Irbesartan
,10934672,time to peak serum concentration,The time to peak serum concentration for both treatments was 3 hours.,Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934672/),h,3,181397,DB01029,Irbesartan
,26839805,flow rate,"After solid phase extraction (SPE), analytes and ISs were separated on an Agilent Poroshell 120, EC-C18 (50 mm × 4.6 mm, i.d., 2.7 μm) column with a mobile phase consisting of methanol/water (85:15, v/v) containing 5 mmol/L ammonium formate and 0.1% formic acid at a flow rate of 0.4 mL/min.","Simultaneous Determination and Pharmacokinetic Study of Losartan, Losartan Carboxylic Acid, Ramipril, Ramiprilat, and Hydrochlorothiazide in Rat Plasma by a Liquid Chromatography/Tandem Mass Spectrometry Method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839805/),[ml] / [min],0.4,182648,DB01029,Irbesartan
,14646353,Delta HR,"IRB (10 mg.kg(-1) i.v.) induced a rapid decrease of the heart rate (HR) in the ACo animals (Delta HR -19.2 +/- 2.0 bpm, n = 6; p < 0.05 vs. basal HR), but not in the SO rats (Delta HR -6.7 +/- 5.1 bpm, n = 6).",Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646353/),b,6,183481,DB01029,Irbesartan
,14646353,Ke,"Analysis of blood samples showed a lower constant of elimination of IRB in ACo rats (Ke 0.67 +/- 0.28 h(-1), n = 5; p < 0.05) than in SO rats (Ke 1.72 +/- 0.30 h(-1), n = 6).",Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646353/),1/[h],0.67,183482,DB01029,Irbesartan
,14646353,Ke,"Analysis of blood samples showed a lower constant of elimination of IRB in ACo rats (Ke 0.67 +/- 0.28 h(-1), n = 5; p < 0.05) than in SO rats (Ke 1.72 +/- 0.30 h(-1), n = 6).",Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646353/),1/[h],1.72,183483,DB01029,Irbesartan
,14646353,area under the curve,"Also, a greater distribution of IRB in the anterior hypothalamus was seen in the ACo rats (area under the curve 32 +/- 4 ng.ml(-1).",Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646353/),[ng] / [ml],32,183484,DB01029,Irbesartan
,14646353,area under the curve,"h(-1), n = 6; p < 0.05) than in the SO rats (area under the curve 12 +/- 1 ng.ml(-1).",Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646353/),[ng] / [ml],12,183485,DB01029,Irbesartan
,14646353,protein binding,"The protein binding of IRB was similar in both experimental groups (SO rats 7.1 +/- 1.2%, n = 6; ACo rats 7.7 +/- 1.5%, n = 6).",Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646353/),%,7.1,183486,DB01029,Irbesartan
,14646353,protein binding,"The protein binding of IRB was similar in both experimental groups (SO rats 7.1 +/- 1.2%, n = 6; ACo rats 7.7 +/- 1.5%, n = 6).",Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646353/),%,7.7,183487,DB01029,Irbesartan
,18307734,bioavailability,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),%,2.6 and 5.0,185713,DB01029,Irbesartan
,18307734,IC50,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),[nM] / [l],0.6,185714,DB01029,Irbesartan
,18307734,plasma half-life,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),h,23-36,185715,DB01029,Irbesartan
,15564789,AUC,"Hypothalamic distribution of IRB was greater in ACo (AUC: 730 +/- 130 ng x ml(-1) h(-1), n = 5, p < 0.05 vs. SO rats) than in SO animals (AUC: 283 +/- 87 ng x ml(-1) h(-1), n = 5).",Hypothalamic antihypertensive effect of irbesartan in chronic aortic coarctated rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564789/),[ng] / [h·ml],730,202380,DB01029,Irbesartan
,15564789,AUC,"Hypothalamic distribution of IRB was greater in ACo (AUC: 730 +/- 130 ng x ml(-1) h(-1), n = 5, p < 0.05 vs. SO rats) than in SO animals (AUC: 283 +/- 87 ng x ml(-1) h(-1), n = 5).",Hypothalamic antihypertensive effect of irbesartan in chronic aortic coarctated rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564789/),[ng] / [h·ml],283,202381,DB01029,Irbesartan
,29403738,flow rate,The reconstituted samples were chromatographed on a C18 column by using a 80:20 (v/v) mixture of acetonitrile and 0.1% formic acid as the mobile phase at a flow rate of 0.8 mL/min.,Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403738/),[ml] / [min],0.8,208533,DB01029,Irbesartan
,29403738,run time,A run time of 2.7 min for each sample made it possible to analyze more than 300 plasma samples per day.,Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403738/),min,2.7,208534,DB01029,Irbesartan
,16413241,cumulative excretion,"The 24-hour urine AcSDKP cumulative excretion increased significantly more after 25 mg AVE7688 (919 nmol [95% confidence interval (CI), 803-1052 nmol], P < .05) than after 5 mg AVE7688 (706 nmol [95% CI, 612-813 nmol]) or 10 mg ramipril (511 nmol [95% CI, 440-593 nmol]).",Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413241/),nM,919,226667,DB01029,Irbesartan
,16413241,cumulative excretion,"The 24-hour urine AcSDKP cumulative excretion increased significantly more after 25 mg AVE7688 (919 nmol [95% confidence interval (CI), 803-1052 nmol], P < .05) than after 5 mg AVE7688 (706 nmol [95% CI, 612-813 nmol]) or 10 mg ramipril (511 nmol [95% CI, 440-593 nmol]).",Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413241/),nM,706,226668,DB01029,Irbesartan
,16413241,cumulative excretion,"The 24-hour urine AcSDKP cumulative excretion increased significantly more after 25 mg AVE7688 (919 nmol [95% confidence interval (CI), 803-1052 nmol], P < .05) than after 5 mg AVE7688 (706 nmol [95% CI, 612-813 nmol]) or 10 mg ramipril (511 nmol [95% CI, 440-593 nmol]).",Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413241/),nM,511,226669,DB01029,Irbesartan
,16413241,plasma active renin concentration,"In the low-salt panel the rise in plasma active renin concentration achieved 24 hours after dosing by 25 mg AVE7688 (247 pg/mL [95% CI, 157-389 pg/mL], P < .05) was significantly higher than that achieved by 5 mg AVE7688 (129 pg/mL [95% CI, 75-221 pg/mL]) or 10 mg ramipril (113 pg/mL [95% CI, 67-193 pg/mL]), which did not differ.",Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413241/),[pg] / [ml],247,226670,DB01029,Irbesartan
,16413241,plasma active renin concentration,"In the low-salt panel the rise in plasma active renin concentration achieved 24 hours after dosing by 25 mg AVE7688 (247 pg/mL [95% CI, 157-389 pg/mL], P < .05) was significantly higher than that achieved by 5 mg AVE7688 (129 pg/mL [95% CI, 75-221 pg/mL]) or 10 mg ramipril (113 pg/mL [95% CI, 67-193 pg/mL]), which did not differ.",Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413241/),[pg] / [ml],129,226671,DB01029,Irbesartan
,16413241,plasma active renin concentration,"In the low-salt panel the rise in plasma active renin concentration achieved 24 hours after dosing by 25 mg AVE7688 (247 pg/mL [95% CI, 157-389 pg/mL], P < .05) was significantly higher than that achieved by 5 mg AVE7688 (129 pg/mL [95% CI, 75-221 pg/mL]) or 10 mg ramipril (113 pg/mL [95% CI, 67-193 pg/mL]), which did not differ.",Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413241/),[pg] / [ml],113,226672,DB01029,Irbesartan
,17118719,flow rate,"Chromatographic separation was achieved on an ODS-C-18 column (100 mm x 4.6 mm i.d., particle size 5 microm) using isocratic elution (at flow rate 1.25 ml/min).",Liquid chromatographic determination of irbesartan in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118719/),[ml] / [min],1.25,228127,DB01029,Irbesartan
,17118719,total time,"The peak was detected using a fluorescence detector set at Ex 259 nm and Em 385 nm, and the total time for a chromatographic separation was approximately 13 min.",Liquid chromatographic determination of irbesartan in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118719/),min,13,228128,DB01029,Irbesartan
,17118719,recoveries,Mean recoveries were 73.3-77.1% with coefficients of variation of 3.7-6.3%.,Liquid chromatographic determination of irbesartan in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118719/),%,73.3-77.1,228129,DB01029,Irbesartan
>,17118719,Stability,"Stability of irbesartan in plasma was >89%, with no evidence of degradation during sample processing and 60 days storage in a deep freezer at -70 degrees C.",Liquid chromatographic determination of irbesartan in human plasma. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118719/),%,89,228130,DB01029,Irbesartan
,23781473,flow rate,"The reconstituted samples were chromatographed on a C18 column by using an 85:15, v/v mixture of methanol and 0.1% v/v formic acid as the mobile phase at a flow rate of 1.0 mL/min.","Simultaneous determination of losartan, losartan acid and amlodipine in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23781473/),[ml] / [min],1.0,230210,DB01029,Irbesartan
,23781473,run time,A run time of 2.5 min for each sample made it possible to analyze more than 300 plasma samples per day.,"Simultaneous determination of losartan, losartan acid and amlodipine in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23781473/),min,2.5,230211,DB01029,Irbesartan
,30549068,recovery,Average recovery of the extraction procedure was 94.8%.,Determination of olanzapine for therapeutic drug monitoring in schizophrenia patients by LC/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30549068/),%,94.8,238267,DB01029,Irbesartan
,30549068,flow rate,"Chromatographic separation was performed on reversed-phase C18 column (250 × 2.0 mm, 5 μm) using mixture of deionized water (trifluoro acetic acid 0.1%)-acetonitrile (20:80, v/v) as mobile phase at a flow rate of 1 mL/min.",Determination of olanzapine for therapeutic drug monitoring in schizophrenia patients by LC/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30549068/),[ml] / [min],1,238268,DB01029,Irbesartan
,30549068,total run time,Irbesartan was used as internal standart and total run time was 2.5 min.,Determination of olanzapine for therapeutic drug monitoring in schizophrenia patients by LC/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30549068/),min,2.5,238269,DB01029,Irbesartan
,22579001,Km,The Km and Vmax of indapamide metabolism were 114.35 ± 3.47 μM and 23.13 ± 6.61 μmol/g/min.,Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),μM,114.35,239835,DB01029,Irbesartan
,22579001,Vmax,The Km and Vmax of indapamide metabolism were 114.35 ± 3.47 μM and 23.13 ± 6.61 μmol/g/min.,Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),[μM] / [g·min],23.13,239836,DB01029,Irbesartan
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,82.6,239837,DB01029,Irbesartan
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,72,239838,DB01029,Irbesartan
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,95,239839,DB01029,Irbesartan
,24215334,globule size,"The optimized batch of IRB-loaded SNEDDS comprised of 31.62% w/w of Capryol 90 as oil phase, 49.90% w/w Cremophor RH40 as surfactant and 18.48% w/w of Transcutol P as cosurfactant exemplified a mean globule size as 23.94 nm.",Quality by design approach for oral bioavailability enhancement of irbesartan by self-nanoemulsifying tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24215334/),nm,23.94,246837,DB01029,Irbesartan
,18399713,"dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],375.5,250691,DB01029,Irbesartan
,18399713,"dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],548.5,250692,DB01029,Irbesartan
,18399713,"AUC(24,ss)/D","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],352.3,250693,DB01029,Irbesartan
,18399713,"AUC(24,ss)/D","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],487.6,250694,DB01029,Irbesartan
,18399713,"AUC(24,ss)/D","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],359.5,250695,DB01029,Irbesartan
,18399713,"AUC(24,ss)/D","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],547.3,250696,DB01029,Irbesartan
,19230599,CL/F,"The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted = 9 h; observed = 10-20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted = 456 L; observed = 260 L).","Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19230599/),[l] / [h],18,250838,DB01029,Irbesartan
,19230599,CL/F,"The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted = 9 h; observed = 10-20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted = 456 L; observed = 260 L).","Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19230599/),[l] / [h],22.2,250839,DB01029,Irbesartan
,19230599,T1/2,"The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted = 9 h; observed = 10-20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted = 456 L; observed = 260 L).","Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19230599/),h,9,250840,DB01029,Irbesartan
,19230599,T1/2,"The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted = 9 h; observed = 10-20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted = 456 L; observed = 260 L).","Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19230599/),h,10-20,250841,DB01029,Irbesartan
,19230599,V/F,"The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted = 9 h; observed = 10-20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted = 456 L; observed = 260 L).","Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19230599/),l,456,250842,DB01029,Irbesartan
,19230599,V/F,"The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted = 9 h; observed = 10-20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted = 456 L; observed = 260 L).","Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19230599/),l,260,250843,DB01029,Irbesartan
,9532516,half-life,Irbesartan is a specific AT1 receptor antagonist with rapid oral bioavailability (peak plasma concentrations occurring at 1.5-2 h after administration) and a long half-life (11-15 h) that provides 24-h blood pressure control with a single daily dose.,Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9532516/),h,11-15,265836,DB01029,Irbesartan
